ACRV Erick Gamelin sold Acrivon Therapeutics, Inc. shares — SEC Form 4SELLAcrivon Therapeutics, Inc.

Erick Gamelin, Chief Development Officer at Acrivon Therapeutics, Inc. (ACRV), sold 400 shares at $2.01 ($804) on 2026-08-18, disclosed to the SEC on 2026-08-20.

SEC EDGAR Filing

0000905148-26-003838

View on SEC EDGAR

Trade context

Open-market sale of $804 ACRV by Chief Development Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.

Modest58/100

Nothing distinguishes this filing.

Selling the RipOpportunistic Sell

Filing Info

Filed2026-08-20

Traded2026-08-18

Accession0000905148-26-003838

SourceSEC EDGAR (Live)

Insider

NameErick Gamelin

TitleChief Development Officer

PIT GradeInsiderUnrated

View Company View Insider

Get an email when an insider at ACRV files

Free account. Follow ACRV and up to 10 more companies.

Follow ACRV for free

ACRV Erick Gamelin sold Acrivon Therapeutics, Inc. shares — SEC Form 4SELLAcrivon Therapeutics, Inc.

Filing Info

Insider

Trade Details

Outcomes